| 产品名称： | 7D3A.2 |
|---|---|
| 商品货号： | TS212796 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody is specific for the structural protein VP7. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against VP7 of bluetongue virus |
| Cellular Products： | immunoglobulin; monoclonal antibody; against VP7 of bluetongue virus |
| Tumorigenic： | Yes |
| Effects： | Yes, in BALB/c mice |
| Comments： | Animals were immunized with bluetongue virus (serotype 17). Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody is specific for the structural protein VP7. |
| Complete Growth Medium： | Dulbeccos modified Eagles medium with 4.5 g/L glucose, 2 mM L-glutamine and 1 mM sodium pyruvate, 90%; fetal bovine serum, 10%
|
| Subculturing： | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 6 x 104 viable cells/mL.xa0 Maintain cultures at a cell concentration between 5 x 104 and 4 x 105 cells/mL. Cell density can reach 1 x 106 cells/mL for antibody production. Medium Renewal: Two to three times weekly |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG2b |
| Name of Depositor： | JA House |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Appleton JA, Letchworth GJ. Monoclonal antibody analysis of serotype-restricted and unrestricted bluetongue viral antigenic determinants. Virology 124: 286-299, 1983. PubMed: 6186076 House C, et al. Detection of bluetongue group-specific antibody by competitive ELISA. J. Vet. Diagn. Invest. 2: 137-139, 1990. PubMed: 1965579 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 7D3A.2 |
|---|---|
| 商品货号： | TS212796 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody is specific for the structural protein VP7. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against VP7 of bluetongue virus |
| Cellular Products： | immunoglobulin; monoclonal antibody; against VP7 of bluetongue virus |
| Tumorigenic： | Yes |
| Effects： | Yes, in BALB/c mice |
| Comments： | Animals were immunized with bluetongue virus (serotype 17). Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody is specific for the structural protein VP7. |
| Complete Growth Medium： | Dulbeccos modified Eagles medium with 4.5 g/L glucose, 2 mM L-glutamine and 1 mM sodium pyruvate, 90%; fetal bovine serum, 10%
|
| Subculturing： | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 6 x 104 viable cells/mL.xa0 Maintain cultures at a cell concentration between 5 x 104 and 4 x 105 cells/mL. Cell density can reach 1 x 106 cells/mL for antibody production. Medium Renewal: Two to three times weekly |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG2b |
| Name of Depositor： | JA House |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Appleton JA, Letchworth GJ. Monoclonal antibody analysis of serotype-restricted and unrestricted bluetongue viral antigenic determinants. Virology 124: 286-299, 1983. PubMed: 6186076 House C, et al. Detection of bluetongue group-specific antibody by competitive ELISA. J. Vet. Diagn. Invest. 2: 137-139, 1990. PubMed: 1965579 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
